Abstract
dc:descriptionFabry disease is a progressive, life-threatening metabolic disorder resulting from a defect in the gene encoding the enzyme α-galactosidase A and its clinical course is characterized by different phases and variety in the evolution of disease manifestations. First symptoms generally appear in childhood or early adolescence and are followed by signs of renal and cardiac involvement. Severe morbidity develops later in adulthood causing premature mortality. We report the clinical and biochemical characteristics of 15 male and 5 female patients from 10 unrelated families who represent almost the entire cohort of known Fabry patients in Greece. Despite the presence of early symptoms in almost every patient (mean age at onset of symptoms 15,6 years, range 9-20), the diagnosis was delayed for a mean of about 18 years (mean age of diagnosis 36 years, range 15-60). Renal manifestations were present in 18 patients [90% proteinuria (>150 mg/day), 50% impaired GFR (<60mL/min) and 20% ESRD], Cardiac involvement was found in 85% of patients and manifested as cardiac hypertrophy (67,5%), valvular abnormalities (50%) and arrhythmias (30%). Acroparesthesias (75%), angiokeratomas (60%), hypoidrosis (40%) and ocular dystrophy (40%) represent the most frequent, remains clinical findings in our cohort. Enzyme Replacement Therapy (ERT) was initiated at different times in fifteen patients and eight of them (age 39±8) completed 3 years of follow up. All patients are treated with agalsidase beta (Fabrazyme™) at a dose of 1mg/kg. Treatment gave a constant reduction in plasma Gb3 levels. Thirty-six months of therapy did not change renal function and proteinuria. Cardiac hypertrophy was improved and enzyme infusions were well tolerated despite formation of antibodies. In conclusion, our study has revealed that ERT clears Gb3 from plasma, stabilizes renal function and proteinuria and improves LVH. ERT is safe and should de started as early as possible to delay organ damage. The diagnostic delay, also demonstrated in our study, compromises the optimal and comprehensive treatment of this progressive disease.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Andrikos, Aimilios
- Ανδρίκος, Αιμίλιος
Subjects
dc:subject × 15- Λυσοσωμικές νόσοι εναπόθεσης
- Γαλακτοζιδάση άλφα
- Χρόνια νεφρική νόσος
- Αγγειοκεράτωμα
- Θεραπεία ενζυμικής υποκατάστασης
- Thesaurismosis
- Galactosidase alpha
- Glycosphingolipids
- Chronic kidney disease
- Angiokeratoma
- Enzyme replacement therapy
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17819